Is Feeding During Therapeutic Hypothermia Safe and Can Improve Outcomes in Infants With Hypoxic-ischaemic Encephalopathy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeUp to 6
SponsorNutricia Foundation

About this trial

Therapeutic hypothermia (TH) is the standard of care for newborns with moderate to severe hypoxic-ischaemic encephalopathy (HIE) born at 35 weeks or more of gestation. Many neonatal units do not use enteral feeding during TH, in fear of increased risk of complications. Withholding enteral feedings during TH lacks supporting evidence. The aim of the study is to determine if enteral feeding during TH in patients with HIE is safe and assess its effects. Investigators will perform multicenter randomized controlled study in level III neonatal intensive care units on infants qualified for TH. Infants will be randomized into 2 groups: (1) unfed during 72 hours of TH; (2) fed group, which will start receive enteral feeding with mother milk or human donor breast milk at 10 ml/kg/day during first day of TH, 20 ml/kg/day during second day, 30 ml/kg/day during third day. The primary outcome will be (1) combined necrotizing enterocolitis or death, (2) length of hospital stay. The secondary outcomes will be (1) time to full enteral feeding, (2) late-onset sepsis, (3) Test of Infant Motor Performance scoring, (4) MRI scoring, (5) MR spectroscopy parameters.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

35 weeks or more gestational age

< 6 hours post birth

Metabolic or mixed acidosis with a pH of ≤7.0 or a base deficit ≥16 mmol/L in an umbilical cord blood sample or any blood obtained within first hour after birth

10-minute Apgar score of ≤5

Disqualifiers

Critical general condition

Aneuploidies (13 th , 18 th , 21 st )

Birth weight <1800 g

Severe congenital defects with poor prognosis

Trial design

Design model

Parallel

Treatments tested in this trial

  • enteral feeding with mother milk or human donor breast milk

    Other intervention

    The experimental group will start enteral feeding with mother milk or human donor breast milk if mother milk is not accesible during the first day of therapeutic hypothermia.

Treatment groups

104 Participants
are divided into 2 treatment groups
Group A: control groupNo intervention 0 interventions
Group B: experimental groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Combined Necrotizing enterocolitis or death

Necrotizing enterocolitis will be defined by the modified Bell's staging criteria (stage II or stage III)

Time frame
from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, during hospital stay, an average of 8 weeks
2

Length of hospital stay

Time frame
assessed from day of birth until discharge from hospital, an average of 8 weeks

Secondary outcomes

1

Time to full enteral feeding

full enteral feeding defined as newborn infants receive all of their prescribed nutrition as milk feeds and do not receive any supplemental parenteral fluids or nutrition

Time frame
assessed from day of birth until discharge from hospital, an average of 8 weeks
2

Late-onset sepsis

defined as sepsis occurring at or after 72 hours of life

Time frame
assessed from day of birth until discharge from hospital, an average of 8 weeks
3

Test of Infant Motor Performance scoring

Time frame
assessed from day of birth until discharge from hospital, an average of 8 weeks
4

MRI scoring

Using MRI scoring system by Rutherford et al., classifying the severity of injury in the basal ganglia and thalami (BGT), cortex (CX), white matter (WM) (each on a scale of 0-3) and posterior limb of the internal capsule (PLIC) (scale 0-2), the higher number indicating more severe abnormality. Total injury score (TIS) will be the sum of these regional scores (scale of 0-11)

Time frame
assessed until the end of the third month of life

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.